PROCEPT BioRobotics vs SkinHealth Systems
PRCT and SKIN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRCT and SKIN compare
PROCEPT BioRobotics is the larger company, worth 12 times as much as SkinHealth Systems ($1.3B against $109M).
PROCEPT BioRobotics grew revenue faster over the last twelve months (17.5% versus −4.4% for SkinHealth Systems).
SkinHealth Systems keeps more of each dollar of sales as profit, with a net margin of −6.3% compared with −32.6% at PROCEPT BioRobotics.
PROCEPT BioRobotics scores higher on the StockData Score (9 against 8 for SkinHealth Systems), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRCT | SKIN |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $109M |
| Share price | $23.34 | $16.67 |
| Change, 1 year | −24.6% | −39.6% |
| Change, 5 years | −42.6% | −97.1% |
| Beta (5Y) | 1.30 | 1.60 |
| Employees | 888 | 613 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 2 | 3 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.8× | 0.4× (better) |
| P/B | 4.1× | 1.9× (better) |
| EV/EBITDA | – | −0.6× |
| P/FCF | – | 4.8× |
| FCF yield | −6.4% | 20.9% (better) |
| Fair value | $48.08 | $32.65 |
| Margin of safety | 51.5% (better) | 48.9% |
| Growth | ||
| Revenue growth (TTM) | 17.5% (better) | −4.4% |
| Revenue growth, 5Y average | 109% (better) | 20.4% |
| Profitability | ||
| Gross margin | 64.7% | 67.2% (better) |
| Operating margin | −33.6% | 2.4% (better) |
| Net margin | −32.6% | −6.3% (better) |
| FCF margin | −24.1% | 7.9% (better) |
| Return on equity | −32.4% | −30.1% (better) |
| Return on invested capital | −62.4% | – |
| Financial health | ||
| Debt / equity | 0.16 | – |
| Interest coverage | −34.7× | 0.3× (better) |
| Current ratio | 5.89 (better) | 2.89 |
| Altman Z-score | 4.18 (better) | −0.50 |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 95.8% | 51.5% |
| Held by insiders | 4.8% | – |
| Insider net buying, 12 months | $10.3M | – |
| Short interest, % of float | 14.4% | – |
Go deeper
- PRCT stock overview
- PRCT income statement
- PRCT valuation and score
- SKIN stock overview
- SKIN income statement
- SKIN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.